The GIFT Nifty futures, which is an early indicator of the Nifty50 index, was trading higher by 476 points at 22,956 indicating that the domestic benchmark indices are likely to make a positive start on Friday.

On Wednesday, 9 April, Domestic benchmark indices S&P BSE Sensex slumped by 380 points or 0.51% and settled at 73,847, while the Nifty50 traded 0.61% lower by 137 points, settling at 22,399.

Here are some stocks that are likely to remain in focus on 11 April.

BHEL: The company has announced the signing of a Memorandum of Understanding (MoU) with Nuovo Pignone International S.r.l. to address compressor revamp opportunities in India’s fertilizer sector.

Coromandel International: Coromandel has deepened its long-standing collaboration with Saudi-based mining giant Ma’aden, one of the leading global producers of phosphate fertilizers by signing a Memorandum of Understanding (MoU). This strategic alliance is aimed at securing a steady and timely supply of Di-Ammonium Phosphate (DAP) and NP/NPK fertilizers for farmers across India.

Biocon: Biocon Biologics, the subsidiary of the company, has announced securing approval from the US Food and Drug Administration (USFDA) Jobevne, which is used to treat various types of cancer. 

NBCC: The company has announced selling 1,185 residential units at Aspire Dream Valley, Phase III, Greater Noida (West), UP via an e-auction, achieving a total sale of Rs 1,504.69 crore. 

Tata Consultancy Services: In its quarterly earnings for January-March, the company reported a 1.7% year-on-year decline in net profit to Rs 12,224 crore due to delays in decision-making, rising uncertainty, and project ramp-downs. 

JSW Energy: The company has announced that it had successfully acquired a 4.7 GW renewable energy platform from O2 Power Pooling Pte. Ltd. for an enterprise value of roughly Rs 12,468 crore through its wholly owned subsidiary JSW Neo Energy. 

Aurobindo Pharma: The subsidiary of the company, CuraTeQ Biologics, has announced the completion of a Phase-1 pharmacokinetic (PK) and pharmacodynamic (PD) study that targets the critical protein in the lifecycle of osteoclasts—cells that break down bone.

Infosys: The company has announced a strategic partnership with AIB to deliver application development and maintenance services, AI-power tooling, and agile practices.

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!